text: CNS involvement can occur during any stage of<unk> . However, CSF laboratory abnormalities are common in persons with early<unk> , even in the absence of clinical neurological findings. No evidence exists to support variation from recommended treatment for early<unk>  for patients found to have such abnormalities. If clinical evidence of neurologic involvement is observed (e.g., cognitive dysfunction, motor or sensory deficits, ophthalmic or auditory symptoms, cranial nerve palsies, and symptoms or signs of meningitis), a CSF examination should be performed.<unk> ic uveitis or other ocular manifestations frequently are associated with<unk>  and should be managed according to the treatment recommendations for<unk> . Patients who have<unk>  or<unk> ic eye disease (e.g., uveitis, neuroretinitis, and optic neuritis) should be treated with the recommended regimen for<unk> ; those with eye disease should be managed in collaboration with an ophthalmologist. A CSF examination should be performed for all patients with<unk> ic eye disease to identify those with abnormalities; patients found to have abnormal CSF test results should be provided follow-up CSF examinations to assess treatment response.
option_0: Syphilis management for neurosyphilis
option_1: Syphilis management for latent stage
option_2: Syphilis management for primary and secondary stages
option_3: Syphilis management during pregnancy
option_4: Neurosyphilis medical therapy
option_5: Creutzfeldt-Jakob disease medical therapy
option_6: Syphilis management among HIV-infected persons
option_7: Neurosyphilis MRI